Mebeverine for Pediatric Functional Abdominal Pain: A Randomized, Placebo-Controlled Trial

Table 2

Changes in primary and secondary outcome measures.

	Mebeverine; 𝑛=44[59]	Placebo; 𝑛=43[56]	𝑃 value
Change of pain score
Week 4	−1.9±1.5[−1.4±1.6]	−1.6±1.5[−1.2±1.5]	0.285 [0.786]*
Week 12	−2.2±1.1[−1.5±1.4]	−1.8±1.4[−1.4±1.5]	0.151 [0.544]*
Change of CGI-S
Week 4	−3.1±1.3[−2.3±1.7]	−3.0±1.7[−2.4±1.9]	0.723 [0.630]*
Week 12	−3.1±1.7[−2.2±1.9]	−3.1±1.5[−2.5±1.8]	0.870 [0.336]*
CGI-I score at week 4	2.0±1.2[2.6±1.3]	2.5±1.4[2.8±1.4]	0.057 [0.368]*
CGI-I score at week 12	2.0±1.4[2.6±1.4]	2.4±1.4[2.7±1.4]	0.183 [0.634]*
Response rate at week 4	24 (54.5) [24 (40.6)]	17 (39.5) [30.3]	0.117 [0.469]**
Response rate at week 12	32 (72.7) [32 (54.2)]	23 (53.4) [23 (41.0)]	0.0503 [0.416]**

Data are presented as mean ± SD. Data of the intention to treat analysis are shown in []. CGI-S, CGI-I: Clinical Global Impression Severity and Improvement Scales. *Mann-Whitney 𝑈 test; **Chi-square test.